Global Muscle Relaxant Drugs Market 2017-2021

Global muscle relaxant drugs market forecast

Technavio’s market research analyst predicts the global muscle relaxant drugs market to grow steadily at a CAGR of around 6% by 2021. One of the primary drivers for this market is the presence of a large patient pool willing to adopt muscle relaxant drugs. This has compelled the manufacturers on developing drugs for the treatment of niche indications such as upper limb and lower limb spasticity. For instance, in April 2015, Allergan received expanded label indication for BOTOX for the treatment of adults with upper limb spasticity. Also, the exponential rise in the cases of multiple sclerosis and fibromyalgia will increase the demand for muscle relaxants drugs, which in turn will propel growth in the global muscle relaxant drugs market in the coming years.

  Get A Free Sample 

One of the latest trends gaining traction in this market is the growing popularity of anti-aging treatments among the population. It has been observed that individuals are more focused on drugs that target specific problems caused by aging such as wrinkles, which require facial muscle relaxants for the treatment. Consumers, especially the older population, are looking for products to maintain and improve their appearance. Moreover, the rise in the aging population is expected to drive the demand for muscle relaxant drug market during the forecast period.

Muscle relaxant drugs market: Competitive landscape and key vendors

The global muscle relaxant drugs market is highly fragmented due to the presence of multiple established international and regional players. Vendors compete primarily on the basis of pricing and new indications. Also, the development of drugs for the treatment of growing spasticity disorders and wrinkles will increase the competition among vendors in the next four years.

Leading vendors in the market are

• Pfizer
• Allergan
• Ipsen Group
• Teva Pharmaceuticals
• Novartis

Segmentation by product category and analysis of the muscle relaxant drugs market

• Skeletal muscle relaxant drugs
• Facial muscle relaxant drugs

During 2016, the skeletal muscle relaxant drugs dominated the muscle relaxant drugs market and accounted for a major part of the overall market share the dominant position of this segment is attributed to the availability of a wide range of drugs for the treatment of spasticity and spasms. Also, the increasing incidence of musculoskeletal disorders such as multiple sclerosis is contributing further to the growth of this segment.

Geographical segmentation and analysis of the muscle relaxant drugs market

• Americas
• APAC
• EMEA

In this market study, analysts have estimated the Americas to dominate the muscle relaxant drugs market during the forecast period. Factors such as the increased demand for anti-aging treatments and the approvals of new label indications are the major contributors to the growth of the muscle relaxant drugs market in the Americas.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global muscle relaxant drugs market?
• What are the key market trends impacting the growth of the global muscle relaxant drugs market?
• What are the challenges to market growth?
• Who are the key vendors in the global muscle relaxant drugs market?
• What are the market opportunities and threats faced by the vendors in the global muscle relaxant drugs market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global muscle relaxant drugs market?

Technavio also offers customization on reports based on specific client requirement.